Preventive treatment for migraine: The present, the future, and the role of monoclonal antibodies

There is no doubt that migraine should be treated; before the
COVID-19 pandemic, migraine ranked second among causes of disability globally, and is a significant source of burden.¹ However, questions on how treatment should proceed still remain. As part of the 7th Congress of the European Academy of Neurology, Profs. Zaza Katsarava (University of Essen-Duisberg, Germany), Hans-